CD19 and non-Hodgkin lymphoma: However, treatment with CD19-directed CAR-T therapy currently results in only 30–40% long-term progression-free survival in aggressive Non-Hodgkin lymphoma (NHL) patients, and the median event-free survival of adult B-cell ALL patients is only 6.1 months [22, 23].